Analysis of filovirus entry into vero E6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 2, 2007, Pages

  Sanchez, Anthony ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMILORIDE; AMMONIUM CHLORIDE; ARSENOSOBENZENE; BAFILOMYCIN A1; CATHEPSIN B; CATHEPSIN B INHIBITOR; CATHEPSIN L; CHLOROQUINE; CHLORPROMAZINE; CLATHRIN; CYSTEINE PROTEINASE INHIBITOR; CYTOCHALASIN D; DANSYLCADAVERINE; METHYL BETA CYCLODEXTRIN; MONENSIN; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE METHYL ESTER; N BENZYLOXYCARBONYLPHENYLALANYL TERT BUTYLTYROSYLDIAZOMETHYLKETONE; NOCODAZOLE; NYSTATIN; PACLITAXEL; UNCLASSIFIED DRUG; WORTMANNIN; CATHEPSIN; CYSTEINE PROTEINASE;

ACIDIFICATION; ACTIN FILAMENT; CAVEOLA; CONFERENCE PAPER; CONTROLLED STUDY; ENDOCYTOSIS; FILOVIRUS; FLUORESCENT ANTIBODY TECHNIQUE; HOST CELL; IMMUNOASSAY; MICROTUBULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VERO CELL; VIRUS ENTRY; VIRUS INHIBITION; ANIMAL; ARTICLE; CERCOPITHECUS; ENDOSOME; FILOVIRIDAE; HAPLORHINI; METABOLISM; PHYSIOLOGY; VIROLOGY;

ANIMALS; CATHEPSIN B; CATHEPSINS; CERCOPITHECUS AETHIOPS; CYSTEINE ENDOPEPTIDASES; ENDOCYTOSIS; ENDOSOMES; FILOVIRIDAE; HAPLORHINI; VERO CELLS;

EID: 38449106461     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520597     Document Type: Conference Paper

References (27)

1. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields virology. 5th ed. Vol 1. Philadelphia: Wolterrs Kluwer/Lippincott Williams and Wilkins, 2007:1409-48.
2. Feldmann H, Geisbert TW, Jahrling PB, et al. Filoviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. Virus taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses. London: Elsevier/Academic Press, 2004.
3. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70.
4. Murphy FA, Nathanson N. An atlas of viral disease pathogenesis. In: Nathanson N, Murphy FA, Ahmed R, et al, eds. Viral pathogenesis. Philadelphia: Lippincott-Raven Press, 1996:433-63.
5. Murphy FA, Simpson DIH, Whitfield SG, et al. Marburg virus infection in monkeys. Lab Invest 1971; 24:279-91.
6. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999; 179(Suppl 1):S199-202.
7. Zaki SR, Goldsmith CD. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 1999; 235:97-116.
8. Chan SY, Empig CJ, Welte FJ, et al. Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 2001; 106:117-26.
9. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol 2000; 74:4933-7.
10. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005; 308:1643-5.
11. Empig CJ, Goldsmith MA. Association of the caveola vesicular system with cellular entry by filoviruses. J Virol 2002; 76:5266-70.
12. Ito H, Watanabe S, Takada A, Kawaoka Y. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J Virol 2001; 75:1576-80.
13. Jeffers SA, Sanders DA, Sanchez A. Covalent modifications of the Ebola virus glycoprotein. J Virol 2002; 76:12463-72.
14. Simmons G, Rennekamp AJ, Chai N, Vandenberghe LH, Riley JL, Bates P. Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection. J Virol 2003; 77:13433-8.
15. Takada A, Fujioka K, Tsuiji M, et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol 2004; 78:2943-7.
16. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003; 13:387-98.
17. Takada A, Robison C, Goto H, et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA 1997; 94:14764-9.
18. Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 1998; 72:3155-60.
19. Yonezawa A, Cavrois M, Greene WC. Studies of Ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. J Virol 2005; 79:918-26.
20. Wool-Lewis RJ, Bates P. Endoproteolytic processing of the Ebola virus envelope glycoprotein: cleavage is not required for function. J Virol 1999; 73:1419-26.
21. Schornberg K, Matsuyama S, Kabsch K, et al. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 2006; 80:4174-8.
22. Weissenhorn W, Carfi A, Lee KH, et al. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 1998; 2:605-16.
23. Ksiazek TG, Rollin PE, Jahrling PB, et al. Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol 1992; 30:947-50.
24. Sieczkarski SB, Whittaker GR. Dissecting virus entry via endocytosis. J Gen Virol 2002; 83:1535-45.
25. Bavari S, Bosio CM, Wiegand E, et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002; 195:593-602.
26. Vago R, Marsden CJ, Lord JM, et al. Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells. FEBS Journal 2005; 272:4983-95.
27. Connolly SA, Lamb RA. Paramyxovirus fusion: real-time measurement of parainfluenza virus 5 virus-cell fusion. Virology 2006; 355:203-12.